Longeveron Inc (LGVN) Cotización

LGVN under $2

LGVN 10 day hourly

LGVN under $3

LGVN...$4.19...🥳

Yes Indeed...🥳

its moving back up nicely now.

LGVN...$3.90s clearing here...Like to see the Break/Hold of $4.35...🥳

LGVN...$4.23...🥳

LGVN...$3.38...14,000 share buy just hit...🥳

LGVN...$3.45...Reversal Candle setting up here...🥳Hit $7 plus days ago...

LGVN...........................................https://stockcharts.com/h-sc/ui?s=LGVN&p=W&b=5&g=0&id=p86431144783

LGVN under $4

Nibble here gap filled

WRONG!!! This PLANET needs to acquire at least a PALTRY knowledge about our Human GENOME!!! The answer to Human AGING & 'Old Timers' disease is in our GENOMES!!! And NOT in the nonsense IGNORANCE of firms like LGVN!!!

u need to increase your knowledge on the matter.

I understand that, but LGVN is NOT a very "real entity" in any respect. (If they were, they would NOT publish such petty events.)

pretty

That is not how it works, the FDA is a very real entity.

Early Barchart 100
https://www.barchart.com/stocks/performance/percent-change/advances?timeFrame=today&viewName=main&screener=overall&orderBy=percentChange&orderDir=desc

LGVN: And yet MORE fluff 'news' from this circus show!! (Heck, they PR purported 'news' after they simply TURN-ON-THE-LIGHTS at their headquarters!!! Oh boy, and today they purportedly got FDA "Fast Track"; and last week it was FDA "Medium Track"; and next week they will get FDA "Ultra-Track" designation. Fluck this firm!!)

LGVN...................................https://stockcharts.com/h-sc/ui?s=LGVN&p=W&b=5&g=0&id=p86431144783

LGVN...$4.44...Starting up again after $3.80 range dip...Hit $7 plus days ago...🥳

Tier 1 buy in. Double from here

Nice move
the shorts are probably going backwards

WHAT A BLESSING, EXCELLENT PRICE ACTION. THANKS*** OUT FOR NOW AND RE ENTER WITH TIME ***

thanks so lot for you kindness !!!

and you ?
you are the hero here, there talk behind and is very clever and the hero

look at the chart, so we see resistant in the way up, a small one by 4,21 and 4,57 and a stronger one by 5,06.... after the 5,06 we are open until 6,50 and 8,24 ... a short can change very quick in the other direction and the stock price flip very quick up

Looking at the 2 year PPS chart and considering the recent FDA news, I see a huge comeback in the making.

$KZIA +248% #DDAmanda Video Analysis - #1 Stock Scanner/Screener



Z

Perhaps this is just a big pump to find bagholders so shorts can cover and move on...

Your posts are devoid of any intelligent comment...

Don't flatter yourself... I wasn't searching you out, but your idiocy was obvious on the replied to thread.

LGVN: And, of course, YOU are still dating Hercules, right???

////////////////////////////////////////////////////////////////////////////////////////////////////////

... and you also have a bridge for sale I suppose,,,,,,

follow the money....not the news

103 million volume is a clear since where we go tomorrow....it´s only a question how high we jump over 6 bucks

5,42 end of the day is possible
tomorrow we see a runner over 7 bucks and more

LGVN: Perhaps a little sign of LIFE here now, suddenly?? (Our USA President --- Mr. Joe --- desperately needs LGVN's stuff!!!)

LGVN: So., Capt. Tim, you too were dumb enough --- like me --- to buy this garbage!!! (And evidently, we BOTH were so stupid that we MISSED the EASY bucks over on that @KZIA monster runner today!!!!)

I CUT THE KNIEF HERE, SHOULD ALMOST BE DONE WITH DILUTION AND I CAN GET OUT*** GREEDINESS

LGVN: Evidently, 'Old Timers' disease, Senile Dementia, inter alia, just ain't TRENDING anymore!!! (Maybe because their PR merely referred to "MILD" cases of 'Old Timers' disease --- vs. severely-advanced cases thereof, like with our (babbling) President Joe!!! And I'm a full-blown DEMOCRAT saying that!!!)

lol

LGVN: Meaning "wee-wee", or like PISS down the toilet??? (What a P.O.S. turd this turned out to be!!!)

Weeeeeee

Only LGVN right now, Bro.

Impressive, also testimony to how unrelated market pricing is to fundamentals. See charts at bottom.


Phase 2 clinical trial underway for Hypoplastic Left Heart Syndrome, which affects approximately 1,000 babies per year

MIAMI, Nov. 18, 2021 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and life-threatening conditions, announced today that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease (RPD) designation for Lomecel-B for the treatment of Hypoplastic Left Heart Syndrome (HLHS), a rare and life-threatening congenital heart defect in infants. Lomecel-B, an investigational allogeneic, bone marrow-derived medicinal signaling cell (MSC) product, is currently being evaluated in a Phase 2 trial.


“We are pleased by FDA’s acknowledgment of the urgent need for a safe and effective treatment for children born with this rare and devastating congenital heart defect,” stated Longeveron co-founder and Chief Science Officer Joshua M. Hare, M.D. “We are encouraged by our Phase 1 clinical data, and the progress being made in the ongoing Phase 2 trial. Lomecel-B represents a unique cell therapy approach that could potentially be administered at the same time as surgery in these critically impacted infants.”

Approximately 1,000 babies are born with HLHS each year in the U.S. HLHS babies have an underdeveloped left ventricle, which impairs the heart’s ability to pump blood throughout the body. HLHS is often fatal without surgical intervention, in which three surgical procedures are performed over the period of about 5 years, to allow the right ventricle to be configured to pump blood to the body. Longeveron is evaluating the safety of Lomecel-B injection into the right ventricle during the second surgery (4 – 6 months of age), and the effect on cardiac function and other health status endpoints.

Longeveron recently reported clinical results from its safety-focused Phase I clinical study of Lomecel-B in HLHS patients. When cardiac surgeons injected Lomecel-B directly into the babies’ hearts at the time of surgery, the cells were well tolerated with no major adverse cardiac events and no infections considered to be related to the investigational treatment.

One hundred percent of infants enrolled in the Phase 1 trial (n=10) were alive and had not required a transplant between 2 – 3.5 years post-surgery. Other measurements of the babies’ health, such as weight gain and growth pattern, matched that of normal healthy babies.

The FDA may grant RPD designation for diseases that primarily affect children ages 18 years old or younger, and fewer than 200,000 individuals in the U.S. Under this program, if the FDA approves Lomecel-B for the treatment of HLHS, Longeveron may be eligible to receive a priority review voucher (PRV) if the application submitted for the product satisfies certain conditions, and under current law, is approved prior to September 30, 2026. Drug companies receiving a PRV can have any subsequent drug or biologic application reviewed and a decision made in six months as opposed to the standard 10 months, potentially accelerating the time to market, or they can sell the PRV to another company. The PRV accelerated review is for patients with serious conditions providing access to a potentially lifesaving or -changing treatment sooner. For companies, it means they can potentially go to market with their product more quickly, and potentially begin generating product revenue.

Infants with HLHS are currently being enrolled in ELPIS II, a 38-subject, phase 2 randomized, double-blind, controlled clinical trial. ELPIS II is being funded in part by a grant from the National Institute of Health’s National Heart, Lung, and Blood Institute (NHLBI; Grant number 1UG3HL148318), in collaboration with Longeveron, and is led by Principal Investigator Sunjay Kaushal, MD, PhD, Division Head, Cardiovascular-Thoracic Surgery, Ann and Robert H. Lurie Children’s Hospital of Chicago. Other participating clinical sites currently open for enrollment are Advocate Children’s Hospital, Park Ridge, IL; Primary Children’s Hospital/University of Utah, Salt Lake City, UT; Children’s Hospital Los Angeles, Los Angeles, CA; and Cincinnati Children’s Hospital Medical Center, Cincinnati, OH.

About Longeveron Inc.

Longeveron is a clinical stage biotechnology company developing cellular therapies for specific aging-related and life-threatening conditions. The Company’s lead investigational product is the LOMECEL-B™ cell-based therapy product (“Lomecel-B”), which is derived from culture-expanded medicinal signaling cells (MSCs) that are sourced from bone marrow of young, healthy adult donors. Longeveron believes that by using the same cells that promote tissue repair, organ maintenance, and immune system function, it can develop safe and effective therapies for some of the most difficult disorders associated with the aging process and other medical disorders. Longeveron is currently sponsoring Phase 1 and 2 clinical trials in the following indications: Aging Frailty, Alzheimer’s disease, the Metabolic Syndrome, Acute Respiratory Distress Syndrome (ARDS), and hypoplastic left heart syndrome (HLHS). The Company’s mission is to advance Lomecel-B and other cell-based product candidates into pivotal Phase 3 trials, with the goal of achieving regulatory approvals, subsequent commercialization and broad use by the healthcare community. Additional information about the Company is available at www.longeveron.com.




https://finance.yahoo.com/news/u-food-drug-administration-approves-130000821.html?fr=yhssrp_catchall

LGVN...$6.22...Watch for $9 here...🥳

Don’t blink

LGVN...$5.26...200MA at $9.40 range...🥳

LGVN...$4.70s clearing here...🥳

LGVN...$4.02...🥳

LGVN...$3.70...Off the $2.23...Alert...🥳

georgie18

Member Level
Re: georgie18 post# 251

Tuesday, July 09, 2024 10:36:32 AM

Post#
253
of 255
LGVN...$2.89...Psar flipped Bullish as LGVN taps the Upper Band...🥳

georgie18

Member Level
Re: None

Monday, July 08, 2024 6:55:48 PM

Post#
251
of 252
LGVN...$2.23...Bouncing off the 50ma post dip in the $1.50 range...🥳